NCT00600964View on ClinicalTrials.gov

A Phase I/II Study of GX15-070MS in Untreated CLL

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

GX15-070MS

A 60-minute or 3-hour IV infusion every 2-3 weeks.

DRUG

GX15-070MS

GX15-070MS at various doses and schedules

Trial Locations (5)

17033

Milton S Hershey Medical Center Penn State Cancer Institute, Hershey

20007

Lombardi Cancer Center, Washington D.C.

77030

UT MD Anderson Cancer Center, Houston

92093

University of CA- San Diego, La Jolla

M5G 2M9

Princess Margaret Hospital, Toronto

Sponsors

Lead Sponsor

Gemin X
All Listed Sponsors
lead

Gemin X

INDUSTRY

NCT00600964 - A Phase I/II Study of GX15-070MS in Untreated CLL | Biotech Hunter | Biotech Hunter